Insider Activity of Merck & Co., Inc. (NYSE:MRK)


Merck & Co., Inc. (NYSE:MRK) belonging to the Medical sector has declined -0.37% and closed its last trading session at $64.15.

The company reported its EPS on 02/02/2017. Currently, the stock has a 1 Year Price Target of $68.55.

The consensus recommendation, according to Zacks Investment research, is 1.68. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.86 and 1.86 respectively.

Merck & Co., Inc. on 02/02/2017 reported its EPS as $0.89 with the analysts projecting the EPS of the stock as $0.89. The company beat the analyst EPS Estimate with the difference of $0. This shows a surprise factor of 0%.

Many analysts have provided their estimated foresights on Merck & Co., Inc. Earnings, with 13 analysts believing the company would generate an Average Estimate of $0.84. Whereas they predicted High and Low Earnings Estimate as $0.9 and $0.73 respectively. While in the same Quarter Previous year, the Actual EPS was $0.89.

Analysts are also projecting an Average Revenue Estimate for Merck & Co., Inc. as $9.27 Billion in the Current Quarter. This estimate is provided by 11 analysts. The High Revenue estimate is predicted as 9.45 Billion, while the Low Revenue Estimate prediction stands at 9.07 Billion. The company’s last year sales total was 9.31 Billion.

For the Current Quarter, the growth estimate for Merck & Co., Inc. is -5.6%, while for the Next Quarter the stock growth estimate is -6.5%. In the past 5 years, the stock showed growth of -0.23% per annum. While for the next 5 years, the growth estimate is 6.49%.

The Company got Initiated by Bryan Garnier on 13-Jan-17 to Buy.

Insider Trades for Merck & Co., Inc. show that the latest trade was made on 5 Feb 2017 where Weeks (Wendell P), the Director completed a transaction type “Sell” in which 5000 shares were traded at a price of $64.51.

6 Insider Sales transactions were made totaling 389423 shares traded.

20 analysts projected Price Targets for Merck & Co., Inc.. The analysts believe that the company stock price could grow as high as $85. The Low Price target projection by analysts is $50 and the Mean Price Target is $68.55.

Merck & Co., Inc. (NYSE:MRK) has the market capitalization of $176.57 Billion. The company rocked its 52-Week High of $65.46 on Nov 10, 2016 and touched its 52-Week Low of $49.24 on Feb 16, 2016. The stock has Return on Assets (ROA) of 0 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of 0 percent.

The stock is currently showing YTD performance of 8.97 Percent. The company has Beta Value of 0.81 and ATR value of 1.05. The Weekly and Monthly Volatility stands at 1.16% and 1.40%.

Company profile:

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.